In our cohorts, we found a significantly higher frequency of IDH1/2/TET2 mutations in “APL-like” NPM1m AML (almost all cases bearing one such mutant) and a significantly higher frequency of DNMT3A mutations in “non-APL-like” NPM1m AML. Here, DNMT3A is linked to acute myeloid leukemia.